Influence of type 2 sodium-glucose co-transporter inhibitors (dapagliflozin) on the indicators of total mortality in patients with type 2 diabetes (CARDIA-MOS study, Moscow)

• Published in: Sakharnyĭ diabet Vol. 25; no. 5; pp. 439 - 448
• Main Authors: Antsiferov, M. B., Demidov, N. A., Balberova, M. A., Lobanova, O. V., Mudrikova, I. G., Gusenbekova, D. G.
• Format: Journal Article
• Language: English
• Published: Endocrinology Research Centre 01-12-2022
• Subjects: chf; ckd; cvd; dapagliflozin; relative risk of death; sglt2i; type 2 diabetes mellitus
• ISSN: 2072-0351; 2072-0378
• DOI: 10.14341/DM12929

BACKGROUND:
The widespread use in clinical practice of drugs with cardio- and nephroprotective properties, in particular, sodium-glucose cotransporter type 2 inhibitors (SGLT2i), is based on the results of large-scale international randomized trials. Meanwhile, there are no data demonstrating the possibility of the influence of these drugs on mortality rates in real clinical practice in Russian patients. To study this issue, a CARDIA-MOS study was conducted on a population of patients with type 2 diabetes (T2DM) in Moscow.
AIM:
To study the effect of SGLT2i on the total mortality of patients with T2DM in Moscow.
MATERIALS AND METHODS
: To assess the frequency of different outcomes, two samples of patients were formed according to predetermined criteria: 1) patients who started therapy with SGLT2i (dapagliflozin) in 2017; 2) a control group of patients corresponding to the main group in terms of key indicators: age, duration of T2DM, presence of cardiovascular diseases, use of insulin therapy, HbA
1c
level.
RESULTS:
Firstly, an analysis of the data of 499 patients who started treatment with dapagliflozin in 2017, as well as 499 patients in the control group (n = 998) was made. The baseline characteristics of the patients were generally comparable. Pre-study SBP and HbA
1c
were worse in the dapagliflozin group. The use of dapagliflozin was associated with a 39% reduction in the relative risk of death from all causes (RR 0.614, 95% CI 0.417–0.903, p = 0.013), led to a decrease in HbA
1c
levels by 0.8% (from 8.5 to 7.7%, p<0.001) for 48 months. observations. The safety profile of dapagliflozin was comparable to that of the control group
CONCLUSION:
The use of dapagliflozin in the treatment of patients with T2DM can reduce overall mortality and improve glycemic control.